Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

UW-SES: A new self-efficacy scale for people with disabilities.
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis - a review.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment.
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus.
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01.
Tysabri prescribing information
Natural History of Multiple Sclerosis Symptoms
The value of specialty pharmaceuticals - a systematic review.
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
Cancer risk in multiple sclerosis: findings from British Columbia, Canada.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Topical Application of Fingolimod Perturbs Cutaneous Inflammation.
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
Autoimmune myelopathies.
In vitro Biological Characterization of IFN-β-1a major Glycoforms.
Molecular targets of FTY720 (fingolimod).
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.

Pages